|
 
- 积分
- 429
- 威望
- 429
- 包包
- 1768
|
本帖最后由 qianqianlaile 于 2011-3-21 11:29 编辑 ' L2 V* G) Y7 A- c
9 z6 T; G, C* e- @INTRODUCTION& w8 B5 X3 g' v5 Z" v
Cell therapy has tremendous potential in regenerative medicine, yet, there are concerns in
4 \" p c x" ?( N) {the utility of cell therapy due to questions regarding different cell harvest and cultivation + [) M- G" ~+ e' L, @
methods (Haack-Sorensen et al., 2008; Mannello and Tonti, 2007). Bone marrow derived % U; R3 ^: Q" i. H# ]: L
stem cells have been identified for a number of years, and there are a number of , d& T# }. i1 V2 w- u8 @9 N
ongoing clinical trials exploring the safety and efficacy of their use for a number of
' n6 J p9 h [4 ?: p0 n+ l4 ?clinical applications (Battiwalla and Hematti, 2009; Sadan et al., 2009; Satija et al., & ~ ]+ T; w- V8 K$ l1 `4 R
2009). There has been an increased interest in recent years in the potential of oral-
. b- l, ?( d2 w1 H9 V, t& ~# oderived stem cells for cell therapy, primarily because they can be derived from a readily
* m3 ?2 S K" }! y0 R0 A0 }5 ?6 mavailable source, extracted teeth (Gronthos et al., 2000; Miura et al., 2003; Seo et al.,
4 k5 r' w* @; A0 z2004). These cells exhibit multipotency and regenerative capacities characteristic of
( Q1 ?# C9 n- U) T# e5 }9 q' F/ kmesenchymal stem cells (Batouli et al., 2003; Shi et al., 2005) and have the capacity to
6 Y O0 c/ x( N* J6 S' O; y6 f1 ^repair and regenerate tooth structures in vivo (Krebsbach and Robey, 2002; Mao et al., 2006).
" ]' W/ K1 f) _ Because oral-derived stem cells have been more recently identified, clinical
( c) W# [- H1 xprotocols are still being developed for their use. Regardless of the specific protocol " I3 e6 v- W6 j U
used, most current cell therapy approaches rely upon ex vivo cell expansion in order to - Y9 V* p- x9 P$ p: R+ ]$ L/ b; d
produce sufficient cell numbers for transplantation. Though a wide variety of protocols % s% n% g! v5 g, ^ U4 w
and culturing methods exist, one common aspect to most of them is the inclusion of
2 p8 Q5 o" Z& oanimal sera for cell expansion, in that it contains a rich source of nutrients and growth 9 o1 t9 L1 e% ^ W
factors (Mannello and Tonti, 2007). Despite the widespread standard use of animal
; W9 G# v5 n& F# |9 vsera for in vitro cell culture (Freshney, 2000), there are several problems which exist * W! x& L2 ^ V2 t- O' y0 o
relative to its use for clinical application.
1 G( e# t' m/ Y8 ]One of the central issues regarding limitations in using animal sera for clinical cell / i3 R1 I" N4 X: S& g3 y/ z
therapy protocols is that its components are highly variable and, in many cases,
( f' H2 O$ U% Gunknown. Though components of sera have identified, it has also been demonstrated
w! H; h' X$ ~( k4 b+ othat consistency between different lots cannot be assured (Price and Gregory, 1982). In & [( ^7 k# v8 y( Q
the context of multipotent stem cells, serum components and concentrations have # p Z1 L8 W6 b1 g' A$ g2 e
significant impact on cell survival and proliferative capacity, phenotype, and multipotent ; D: W8 g4 ]- F2 T) o
potential (Agata et al., 2009; Sotiropoulou et al., 2006). Additionally, for clinical use, the
2 F6 _6 A" F8 y- Pinclusion of xenogeneic serum for cell expansion carries immunological risks associated $ ~( [3 J% Q7 [4 }% m0 w% Y2 b
with the immunogenicity of serum proteins and the potential of transmission of prion
8 {& p0 a1 z% X; d+ F- L( Q9 Ydiseases and zoonoses (Shahdadfar et al., 2005). These concerns have led to efforts 3 H( H- B' l" `$ M
aimed at incorporating FBS alternatives in cell expansion protocols, including the use of
; B) q. \- ?7 iautologous and allogeneic sera, and the proprietary manufacturing of serum-free media
; k! h8 T4 S* mformulations by different companies (Nakamura et al., 2008). Even with these approaches,& z) A4 K: Z/ H& a
there are limitations in the availability of both autologous and allogeneic
5 K z/ d) z7 g1 W! i* W5 Ksera and companies do not freely disclose their proprietary “serum-free” media
$ v/ x4 d; }$ @; V6 F" s" `components. These factors not only prohibit clinical translation, but also limit
, o O# r, W7 U5 o4 m3 |widespread use and study of more basic fundamental questions regarding specific
) ~2 m1 V F/ F( imechanisms involved in the modulation of these media on cell function. As such, there
! b, a# _4 C0 c' n. z1 x$ z7 A! v# S" Pexists a need for the development of chemically-defined media which can propagate the
+ s% T p: f' ~cultivation of stem cells without adversely affecting cell function and phenotype ! Q9 L, _" u9 Y9 J0 ], i
(Mannello and Tonti, 2007)./ j" i( B2 J3 `
In this study, we aimed to develop a serum-free media (K-M) for the expansion o
. o/ n3 i6 H6 A f( X" p. bdental-derived stem cells, including stem cells-derived from exfoliated deciduous (baby)
G7 \. r5 T" e. {8 j6 Fteeth (SHEDs) and periodontal ligament stems cells (PDLSCs). Cell expansion in this
- E1 Y3 d) A% ?/ fmedia was compared to standard FBS containing media used to culture these cells, # n6 D% D! B: a; Y5 ~
as well as three other serum-free media formulations (two of which are commercially available)
2 x- c% w% }$ C' Wused for culture of mesenchymal stem cells. Additionally, through
$ M0 C9 c, s* \/ Idifferentiation assays and microarray analyses, multipotency and differential gene 2 H' k# a7 g/ d: \' I
expression of 84 stem cell associated genes was examined between cells cultured in K-
% S l: ~0 D" O( M1 w5 J" lM vs. those cultured in FBS- containing media. |
|
发表于 2011-3-20 08:21
4 B y& L( w w( X! a
，脑子里也没有独家生产这个概念
，所以没理解。; d. A* }4 |* V